Skip to main content

Table 2 Distribution of Xenobiotic genes polymorphisms in healthy population and PTC cases (n = 223).

From: Polymorphisms of selected Xenobiotic Genes contribute to the development of Papillary Thyroid Cancer susceptibility in Middle Eastern population

Polymorphism

Genotype

Control group

PTC Cases

p*

OR$

(95%CI)

CYP1A1 C4887A

      
 

CC

331 (64.8%)

95 (47%)

   
 

CA

162 (31.7%)

89 (44%)

< 0.0001

1.91

(1.36–2.70)

 

AA

18 (3.5%)

18 (10%)

< 0.001

3.48

(1.74–6.96)

 

CA+AA

180 (35.2%)

107 (53%)

< 0.0001

2.07

(1.49–2.88)

NAT2 G590A

      
 

GG

284 (55.4%)

99 (50%)

   
 

GA

181 (35.3%)

81 (41%)

0.180

1.28

(0.91–1.82)

 

AA

47 (9.2%)

18 (9%)

0.76

1.11

(0.61–1.98)

 

GA+AA

228 (44.5%)

99 (50%)

0.21

1.25

(0.90–1.73)

GSTT1

      
 

P

385 (75%)

96 (46.37%)

   
 

D

128 (25%)

111 (53.62%)

< 0.0001

3.48

(2.48–4.88)

GSTM1

      
 

P

233 (45.4%)

109 (53.7%)

   
 

D

280 (54.6%)

94 (46.3%)

0.047

0.72

(0.52–0.99)

GSTM1+GSTT1

      
 

P

423 (82.8)

159 (78.32%)

   
 

D

88 (17.2%)

48 (23.64%)

0.074

1.45

(0.98–2.16)

  1. * Statistical significance of the differences in the frequency of genotypes was assessed, applying two-sided Fisher's exact test to compare between case and control subjects.
  2. $ The odds ratio (OR) providing a measure for the strength of association demonstrating a particular genotype compared with the control population calculated using the SPSS statistical package (version 11.0).
  3. P = Present and D = Deletion for GSTM1 and GSTT1 gene